These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20460480)

  • 1. Susceptibility loci associated with prostate cancer progression and mortality.
    Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
    Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.
    Sullivan J; Kopp R; Stratton K; Manschreck C; Corines M; Rau-Murthy R; Hayes J; Lincon A; Ashraf A; Thomas T; Schrader K; Gallagher D; Hamilton R; Scher H; Lilja H; Scardino P; Eastham J; Offit K; Vijai J; Klein RJ
    Br J Cancer; 2015 Jun; 113(1):166-72. PubMed ID: 26068399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
    Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.
    Fitzgerald LM; Kwon EM; Koopmeiners JS; Salinas CA; Stanford JL; Ostrander EA
    Clin Cancer Res; 2009 May; 15(9):3231-7. PubMed ID: 19366831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
    Bensen JT; Xu Z; Smith GJ; Mohler JL; Fontham ET; Taylor JA
    Prostate; 2013 Jan; 73(1):11-22. PubMed ID: 22549899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
    Shui IM; Lindström S; Kibel AS; Berndt SI; Campa D; Gerke T; Penney KL; Albanes D; Berg C; Bueno-de-Mesquita HB; Chanock S; Crawford ED; Diver WR; Gapstur SM; Gaziano JM; Giles GG; Henderson B; Hoover R; Johansson M; Le Marchand L; Ma J; Navarro C; Overvad K; Schumacher FR; Severi G; Siddiq A; Stampfer M; Stevens VL; Travis RC; Trichopoulos D; Vineis P; Mucci LA; Yeager M; Giovannucci E; Kraft P
    Eur Urol; 2014 Jun; 65(6):1069-75. PubMed ID: 24411283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
    Reis ST; Viana NI; Leite KR; Diogenes E; Antunes AA; Iscaife A; Nesrallah AJ; Passerotti CC; Srougi V; Pontes-Junior J; Salles ME; Nahas WC; Srougi M
    PLoS One; 2016; 11(12):e0166380. PubMed ID: 27906997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.
    Ahn J; Kibel AS; Park JY; Rebbeck TR; Rennert H; Stanford JL; Ostrander EA; Chanock S; Wang MH; Mittal RD; Isaacs WB; Platz EA; Hayes RB
    Clin Cancer Res; 2011 Mar; 17(5):1075-81. PubMed ID: 21343373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
    Beikzadeh B; Angaji SA; Abolhasani M
    BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer susceptibility variants confer increased risk of disease progression.
    Cheng I; Plummer SJ; Neslund-Dudas C; Klein EA; Casey G; Rybicki BA; Witte JS
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2124-32. PubMed ID: 20651075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.
    Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Juang SH; Bao BY
    Sci Rep; 2015 Feb; 5():8556. PubMed ID: 25707771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.
    Pomerantz MM; Werner L; Xie W; Regan MM; Lee GS; Sun T; Evan C; Petrozziello G; Nakabayashi M; Oh WK; Kantoff PW; Freedman ML
    Cancer Prev Res (Phila); 2011 May; 4(5):719-28. PubMed ID: 21367958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
    Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
    Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
    Perez CA; Chen H; Shyr Y; Courtney R; Zheng W; Cai Q; Hwang M; Jaboin J; Schleicher S; Moretti L; Wills M; Smith JA; Lu B
    J Urol; 2010 May; 183(5):2062-9. PubMed ID: 20303520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death.
    Song X; Ru M; Steinsnyder Z; Tkachuk K; Kopp RP; Sullivan J; Gümüş ZH; Offit K; Joseph V; Klein RJ
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1466-1472. PubMed ID: 35511739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.